Home > BRISA > Search result
COVID-19

In this section you will find the HTA reports produced by RedETSA members in response to the COVID-19 pandemic. For additional resources, please visit PAHO’s website.


Limitation of Liability

The information, products, services, tools and/or opinions shared and expressed on the platform are the sole responsibility of the institutions that produce them, and do not necesarily represent the views of PAHO/WHO.

PAHO/WHO and its Specialized Center BIREME make no warranties nor guarantees the accuracy or truthfulness of the information, products, services and/or tools provided. Users must use these products, services and/or tools at their own risk. In no case will PAHO/WHO and its Specialized Center BIREME be liable for damages, even if they may have been warned and/or prevented.

Terms and conditions of use

Results: 2

Bendamustina como primera línea de tratamiento en Linfoma no Hodgkin Indolente

Instituto de Efectividad Clínica y Sanitaria.
CONTEXTO CLÍNICO: El linfoma es una neoplasia que se origina a partir del crecimiento anormal de los linfocitos, los cuales forman parte del sistema inmunológico. Es la neoplasia sanguínea más frecuente. Clásicamente, se dividen en dos grandes grupos: linfoma de Hodgkin (LH) y linfoma no Hodgkin (LN...
Lymphoma, Non-Hodgkin/drug therapy, Bendamustine Hydrochloride/therapeutic use, Technology Assessment, Biomedical, Cost Efficiency Analysis
Fulltext

Eficacia y seguridad de obinutuzumab más bendamustina en pacientes adultos con linfoma no hodgkin indolente (folicular) refractario o resistente a rituximab

Perú. EsSalud. Instituto de Evaluación de Tecnologías en Salud e Investigación.
INTRODUCCIÓN: El presente informe expone la evaluación del uso del esquema obinutuzumab más bendamustina en el tratamiento del linfoma no Hodgkin indolente (folicular) refractario o resistente a rituximab. Se incluyó el estudio GADOLIN, que, aunque no responde directamente a la pregunta PICO plantead...
Antibodies, Monoclonal/therapeutic use, Bendamustine Hydrochloride/therapeutic use, Rituximab/adverse effects, Lymphoma, Non-Hodgkin/drug therapy, Technology Assessment, Biomedical, Cost Efficiency Analysis
Fulltext